stoxline Quote Chart Rank Option Currency Glossary
  
Erasca, Inc. (ERAS)
2.46  0.06 (2.5%)    02-27 14:47
Open: 2.42
High: 2.615
Volume: 1,208,994
  
Pre. Close: 2.4
Low: 2.4037
Market Cap: 372(M)
Technical analysis
2024-02-27 2:14:03 PM
Short term     
Mid term     
Targets 6-month :  3.05 1-year :  3.56
Resists First :  2.61 Second :  3.05
Pivot price 1.94
Supports First :  2.01 Second :  1.63
MAs MA(5) :  2.21 MA(20) :  1.88
MA(100) :  2.02 MA(250) :  2.46
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  83.8 D(3) :  78.5
RSI RSI(14): 73.3
52-week High :  3.7 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ERAS ] has closed above the upper band by 3.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 80.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.58 - 2.59 2.59 - 2.61
Low: 2.29 - 2.3 2.3 - 2.31
Close: 2.38 - 2.4 2.4 - 2.42
Company Description

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Headline News

Mon, 26 Feb 2024
Is Erasca Inc (ERAS) a Bad Choice in Biotechnology Monday? - InvestorsObserver

Wed, 21 Feb 2024
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Tue, 20 Feb 2024
Is Erasca Inc (ERAS) a Stock to Watch After Gaining 9.29% This Week? - InvestorsObserver

Wed, 14 Feb 2024
Erasca, Novartis team up on cancer drug trials By Investing.com - Investing.com

Thu, 01 Feb 2024
Erasca, Inc. (NASDAQ:ERAS) Short Interest Update - MarketBeat

Tue, 09 Jan 2024
Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 151 (M)
Shares Float 85 (M)
Held by Insiders 22.5 (%)
Held by Institutions 54.2 (%)
Shares Short 10,220 (K)
Shares Short P.Month 9,630 (K)
Stock Financials
EPS -1.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21.1 %
Return on Equity (ttm) -65.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -103 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -1.44
PEG Ratio 0.1
Price to Book value 1.09
Price to Sales 0
Price to Cash Flow -3.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android